Dashboard
Manage Tickers

OLMAOlema Pharmaceuticals, Inc.

Nasdaq olema.com


$ 10.70 $ 0.63 (6.26 %)    

Friday, 03-May-2024 12:36:16 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.44 $ 3.12 (0.72 %)
DIA $ 386.70 $ -0.04 (-0.01 %)
SPY $ 511.09 $ 0.56 (0.11 %)
TLT $ 89.62 $ -0.49 (-0.54 %)
GLD $ 212.58 $ -0.82 (-0.38 %)
$ 10.07
$ 10.52
$ 0.00 x 0
$ 0.00 x 0
$ 10.38 - $ 10.73
$ 5.02 - $ 17.79
968,451
na
455.64M
$ 2.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-11-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-09-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 02-28-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 03-17-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

goldman-sachs-initiates-coverage-on-olema-pharmaceuticals-with-buy-rating-announces-price-target-of-24
Goldman Sachs Initiates Coverage On Olema ...
04/02/2024 11:09:16

Goldman Sachs analyst Richard Law initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announces ...

oppenheimer-reiterates-outperform-on-olema-pharmaceuticals-maintains-21-price-target
Oppenheimer Reiterates Outperform on Olema...
03/12/2024 12:18:02

Oppenheimer analyst Matthew Biegler reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and maintains $21 price...

hc-wainwright--co-maintains-buy-on-olema-pharmaceuticals-lowers-price-target-to-25
HC Wainwright & Co. Maintains Buy on Olema...
03/12/2024 10:39:57

HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price t...

olema-pharmaceuticals-q4-eps-049-misses-048-estimate
Olema Pharmaceuticals Q4 EPS $(0.49) Misse...
03/11/2024 20:04:08

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate ...

eaton-posts-strong-results-joins-ferrari-boot-barn-and-other-big-stocks-moving-higher-on-thursday
Eaton Posts Strong Results, Joins Ferrari,...
02/01/2024 15:46:02

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday.

olema-pharmaceuticals-filed-prospectus-related-to-resale-of-up-to-132m-shares-of-common-stock-held-by-selling-stockholders
Olema Pharmaceuticals Filed Prospectus Rel...
01/31/2024 21:24:06

-S-3

citigroup-initiates-coverage-on-olema-pharmaceuticals-with-buy-rating-announces-price-target-of-20
Citigroup Initiates Coverage On Olema Phar...
01/30/2024 12:33:52

Citigroup analyst Yigal Nochomovitz initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announce...

olema-oncology-nominates-op-3136-as-a-development-candidate
Olema Oncology Nominates OP-3136 As A Deve...
01/08/2024 13:14:43

69m-bet-on-this-healthcare-stock-check-out-these-4-stocks-insiders-are-buying
$6.9M Bet On This Healthcare Stock? Check ...
12/19/2023 11:59:41

Although U.S. stocks closed mostly higher on Monday, there were a few notable insider trades.

insiders-buying-walt-disney-and-3-other-stocks
Insiders Buying Walt Disney And 3 Other St...
12/11/2023 12:17:16

Although U.S. stocks closed higher on Friday, there were a few notable insider trades.

olema-oncology-announces-palazestrant-demonstrates-attractive-combinability-with-cdk46-inhibitors-ribociclib-and-palbociclib-in-phase-1b2-studies
Olema Oncology Announces Palazestrant Demo...
12/05/2023 17:36:57

Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug...

olema-oncology-to-present-new-palazestrant-clinical-data-in-combination-with-cdk46-inhibitors-at-2023-san-antonio-breast-cancer-symposium
Olema Oncology To Present New Palazestrant...
11/28/2023 22:11:08

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
11/27/2023 13:06:58

olema-pharmaceuticals-q3-eps-048-beats-051-estimate
Olema Pharmaceuticals Q3 EPS $(0.48) Beats...
11/07/2023 22:08:09

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of...

treehouse-foods-echostar-hilton-grand-vacations-echostar-and-other-big-stocks-moving-lower-on-monday
TreeHouse Foods, EchoStar, Hilton Grand Va...
11/06/2023 15:27:01

U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big stocks recording losses in ...

olema-oncology-earlier-announced-phase-2-monotherapy-clinical-study-results-for-palazestrant-showed-results-support-continued-development-of-palazestrant-in-the-opera-01-monotherapy-phase-3-pivotal-trial
Olema Oncology Earlier Announced Phase 2 M...
10/22/2023 15:11:40

Olema Pharmaceuticals, Inc. ((&ldquo, Olema&rdquo, , &ldquo, Olema Oncology&rdquo, , or the &ldquo, Company...

wyndham-hotels--resorts-olink-holding-and-other-big-stocks-moving-higher-on-tuesday
Wyndham Hotels & Resorts, Olink Holding An...
10/17/2023 15:40:41

U.S. stocks traded lower, with the Dow Jones falling around 50 points on Tuesday. Here are some big stocks recording gains in t...

olema-oncology-announces-phase-2-monotherapy-clinical-results-of-palazestrant-for-metastatic-breast-cancer-to-be-presented-at-the-2023-esmo-congress
Olema Oncology Announces Phase 2 Monothera...
10/16/2023 11:14:48

olema-pharmaceuticals-announced-new-preclinical-data-regarding-the-discovery-of-novel-compounds-targeting-kat6-an-epigenetic-target-that-is-dysregulated-in-breast-and-other-cancers
Olema Pharmaceuticals Announced New Precli...
10/12/2023 11:03:53

analyst-ratings-for-olema-pharmaceuticals
Analyst Ratings for Olema Pharmaceuticals
10/11/2023 17:01:05

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION